Search

Your search keyword '"Jaffee, E.M."' showing total 23 results
Start Over Author "Jaffee, E.M."
23 results on '"Jaffee, E.M."'

1. 1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes

Author

Medina, J.E., primary, Roussos Torres, E.T., additional, Leal, A., additional, Adleff, V., additional, Lumbard, K., additional, Keefer, L., additional, Carey, J., additional, Brufsky, A., additional, Lorusso, P., additional, Eder, J.P., additional, Chung, V., additional, Downs, M., additional, O'Connor, A., additional, Piekarz, R., additional, Streicher, H., additional, Jaffee, E.M., additional, Scharpf, R.B., additional, Stearns, V., additional, Connolly, R.M., additional, and Velculescu, V.E., additional

Published
2022
Full Text
View/download PDF

2. 964MO Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer (ETCTN-9844)

Author

Roussos Torres, E.T., primary, Leatherman, J., additional, Rafie, C., additional, Brufsky, A., additional, Lorusso, P., additional, Eder, J.P., additional, Chung, V., additional, Yuan, Y., additional, Downs, M., additional, O’Connor, A., additional, Piekarz, R., additional, Streicher, H., additional, Rudek, M.A., additional, Zhu, Q., additional, Fertig, E., additional, Anders, R.A., additional, Cimino-Mathews, A., additional, Jaffee, E.M., additional, Stearns, V., additional, and Connolly, R.M., additional

Published
2021
Full Text
View/download PDF

5. Multiplex Proximal Ligation Assay Identifies Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy

Author

Rao, A.D., primary, Liu, Y., additional, Hsu, C.C., additional, Parekh, A., additional, Rosati, L.M., additional, Ng, K., additional, Hacker-Prietz, A., additional, Zheng, L., additional, Pawlik, T.M., additional, Laheru, D.A., additional, Jaffee, E.M., additional, Weiss, M.J., additional, Le, D.T., additional, Hruban, R.H., additional, De Jesus-Acosta, A., additional, Wolfgang, C.L., additional, Chang, D.T., additional, Koong, A.C., additional, and Herman, J.M., additional

Published
2016
Full Text
View/download PDF

6. Serum Protein Expression and Associations With Conversion to Resectable Status Following Chemotherapy and Stereotactic Body Radiation Therapy in Locally Advanced Pancreatic Adenocarcinoma

Author

Rosati, L.M., primary, Liu, Y., additional, Rao, A.D., additional, Hsu, C.C., additional, Parekh, A., additional, Ng, K., additional, Hacker-Prietz, A., additional, Zheng, L., additional, Laheru, D.A., additional, Jaffee, E.M., additional, Le, D.T., additional, De Jesus-Acosta, A., additional, Hruban, R.H., additional, Pawlik, T.M., additional, Weiss, M.J., additional, Wolfgang, C.L., additional, Chang, D.T., additional, Herman, J.M., additional, and Koong, A.C., additional

Published
2016
Full Text
View/download PDF

7. Dosimetric Correlations with Toxicity in the First Experience Validating Adjuvant Fractionated Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer

Author

Rao, A.D., primary, Parkinson, R., additional, Onners, B., additional, Zheng, L., additional, Le, D.T., additional, Lutz, E., additional, De Jesus-Acosta, A., additional, Hruban, R.H., additional, Hirose, K., additional, Fishman, E.K., additional, Weiss, M.J., additional, Hacker-Prietz, A., additional, Pawlik, T.M., additional, Cameron, J.L., additional, Wolfgang, C.L., additional, Jaffee, E.M., additional, Laheru, D.A., additional, and Herman, J.M., additional

Published
2015
Full Text
View/download PDF

8. Preliminary Results of a Pilot Study Evaluating An Allogeneic GM-CSF Pancreatic Tumor Cell Vaccine (GVAX) and Cytoxan (Cy) With Stereotactic Body Radiation Therapy (SBRT) and Folfirinox (FFX) in Patients With Resected Pancreatic Adenocarcinoma

Author

Herman, J.M., primary, Parkinson, R., additional, Onners, B., additional, Rao, A.D., additional, Zheng, L., additional, Le, D.T., additional, De Jesus-Acosta, A., additional, Lutz, E., additional, Hruban, R.H., additional, Hirose, K., additional, Fishman, E.K., additional, Weiss, M.J., additional, Hacker-Prietz, A., additional, Pawlik, T.M., additional, Cameron, J.L., additional, Wolfgang, C.L., additional, Jaffee, E.M., additional, and Laheru, D.A., additional

Published
2015
Full Text
View/download PDF

9. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine

Author

Zhou, X., Jun, D.Y., Thomas, A.M., Huang, X., Huang, L.-Q., Mautner, J., Mo, W., Robbins, P.F., Pardoll, D.M., and Jaffee, E.M.

Abstract

A phase I clinical trial with granulocyte-macrophage colony-stimulating factor tumor cell vaccines in patients with metastatic renal cell carcinoma (RCC) showed immune cell infiltration at vaccine sites and delayed-type hypersensitivity (DTH) responses to autologous tumor cells indicative of T-cell immunity. To further characterize RCC T-cell responses and identify relevant RCC-associated antigens, we did a detailed analysis of CD8+ T-cell responses in two vaccinated RCC patients who generated the greatest magnitude of DTH response and also displayed a strong clinical response to vaccination (>90% reduction in metastatic tumor volume). Three separate CD8+ T-cell lines (and subsequent derived clones) derived from patient 24 recognized distinct RCC-associated antigens. One recognized a shared HLA-A*0201-restricted antigen expressed by both renal cancer cells and normal kidney cells. This recognition pattern correlated with a positive DTH test to normal kidney cells despite no evidence of impairment of renal function by the patient's remaining kidney after vaccination. A second line recognized a shared HLA-C7-restricted antigen that was IFN-γ inducible. A third line recognized a unique HLA-A*0101-restricted RCC antigen derived from a mutated KIAA1440 gene specific to the tumor. In addition, two independent CTL lines and three clones were also generated from patient 26 and they recognized autologous tumor cells restricted through HLA-A*0205, HLA-A/B/C, and HLA-B/C. These results show that paracrine granulocyte-macrophage colony-stimulating factor tumor vaccines may generate a diverse repertoire of tumor-reactive CD8+ T-cell responses and emphasize the importance of polyvalency in the design of cancer immunotherapies.

Published
2005

10. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., Disis, M.L.A., Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., and Disis, M.L.A.

Abstract

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.

Published
2011
Full Text
View/download PDF

12. Chemotherapy : friend or foe to cancer vaccines?

Author

UCL - MD/MINT - Département de médecine interne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Emens, L.A., Machiels, Jean-Pascal, Reilly, R.T., Jaffee, E.M., UCL - MD/MINT - Département de médecine interne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Emens, L.A., Machiels, Jean-Pascal, Reilly, R.T., and Jaffee, E.M.

Abstract

Cancer vaccines are oil the threshold of taking their place alongside the more traditional cancer treatment modalities of surgery, radiation therapy and chemotherapy. The toxicology and immunopharmacology of therapeutic cancer vaccines, particularly those that secrete granulocyte macrophage colony stimulating factor (GM-CSF), are currently under active clinical investigation. Interestingly drugs traditionally used for tumor cytoreduction can have both positive and negative effects on host immunity. Exploration of the potential pharmacodynamic interactions of antineoplastic drugs with GM-CSF-secreting vaccines has revealed that low doses of some chemotherapeutics can augment the antitumor immunity induced by GM-CSF-secreting vaccines. These interactions will require through preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine.

Published
2001

13. 104

Author

Miyashita, T., primary, Armstrong, T.D., additional, Wang, J., additional, Gibson, M.K., additional, Chen, D.S., additional, Yoshimura, K., additional, Mohebi, P., additional, Marti, G., additional, Montgomery, E.A., additional, Duncan, M., additional, Jaffee, E.M., additional, and Harmon, J.W., additional

Published
2007
Full Text
View/download PDF

14. A multivariate model for identifying risk of early death after Pancreaticoduodenectomy(PDD) and adjuvant therapy for periampullary Adenocarcinoma(PA): importance for understanding post treatment outcomes

Author

Abrams, R.A, primary, Sohn, T.A, additional, Zahurak, M.L, additional, Korman, L.T, additional, Lillemoe, K.D, additional, Jaffee, E.M, additional, Donehower, R.C, additional, Laheru, D, additional, Hruban, R.H, additional, Cameron, J.L, additional, and Yeo, C.J, additional

Published
2002
Full Text
View/download PDF

15. Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer

Author

Simons, J.W., primary, Jaffee, E.M., additional, Weber, C.E., additional, Levitsky, H.J., additional, Nelson, W.G., additional, Carducci, M.A., additional, Lazenby, A.J., additional, Cohen, L.K., additional, Finn, C.C., additional, Clift, S.M., additional, Hauda, K.M., additional, Beck, L.A., additional, Leiferman, K.M., additional, Owens, A.H., additional, Piantadosi, S., additional, Dranoff, G., additional, Mulligan, R.C., additional, Pardoll, D.M., additional, and Marshall, F.F., additional

Published
1998
Full Text
View/download PDF

18. Demonstration of a rational strategy for human prostate cancer gene therapy

Author

Sanda, M.G., Ayyagari, S.R., Jaffee, E.M., Epstein, J.I., Clift, S.L., Cohen, L.K., Dranoff, G., Pardoll, D.M., Mulligan, R.C., and Simons, J.W.

Subjects
Prostate cancer -- Care and treatment, Gene therapy -- Testing, Business, Health care industry
Abstract

SOURCE: Journal of Urology, March 1994;151(3):622-628. According to the authors' abstract of an article published in the Journal of Urology, 'The potential efficacy and clinical feasibility of gene therapy for [...]

Published
1994

19. Controlled release, biodegradable cytokine depots - a new approach in cancer vaccine design

Author

Golumbek, P.T., Azhari, R., Jaffee, E.M., Levitsky, H.I., Lazenby, A., Leong, K., and Pardoll, D.M.

Subjects
Vaccines -- Research, Cytokines -- Health aspects, Immunotherapy -- Research, Business, Health care industry
Abstract

SOURCE: Cancer Research, December 15, 1993;53(24):5841 -5844. According to the authors' abstract of an article published in Cancer Research, 'Experimental studies using murine tumor models have demonstrated that potent systemic [...]

Published
1994

20. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer

Author

Simons, J.W., Jaffee, E.M., Weber, C.E., Levitsky, H.I., Nelson, W.G., Carducci, M.A., Lazenby, A.J., Cohen, L.K., Finn, C.C., Clift, S.M., Hauda, K.M., Beck, L.A., Leiferman, K.M., Owens, A.H., Piantadosi, S., Dranoff, G., and Mulligan, R.C.

Subjects
Carcinoma, Renal cell -- Care and treatment, Cancer vaccines -- Testing, Health, Testing, Care and treatment
Abstract

Simons, J.W.; Jaffee, E.M.; Weber, C.E.; Levitsky, H.I.; Nelson, W.G.; Car- ducci, M.A.; Lazenby, A.J.; Cohen, L.K.; Finn, C.C.; Clift, S.M.; Hauda, K.M.; Beck, L.A.; Leiferman, K.M.; Owens, A.H.; Piantadosi, [...]

Published
1997

21. Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption ionization mass spectrometry

Author

Wood, A.S., Huang, A.Y.C., Cotter, R.J., Pasternack, G.R., Pardoll, D.M., and Jaffee, E.M.

Subjects
HLA histocompatibility antigens -- Health aspects, Vaccines -- Research, Peptides -- Health aspects, Business, Health care industry
Abstract

According to the authors' abstract of an article published in Analytical Biochemistry, 'Cytotoxic T cells (CTL) are known to recognize small peptide fragments of cytoplasmic proteins bound to major histocompatibility [...]

Published
1995

22. Murine tumor vaccines: models for designing human vaccine trials

Author

Jaffee, E.M., Lazenby, A., and Pardoll, D.M.

Subjects
Vaccines -- Research, Clinical trials -- Models, Cancer -- Research, Business, Health care industry
Abstract

According to an abstract submitted by the authors to the 86th Annual Meeting of the American Association for Cancer Research, held March 18-22, 1995, Toronto, Ontario, Canada, 'The past several [...]

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results